The Dipeptidyl Peptidase-4 Inhibitor Des-Fluoro-Sitagliptin Regulates Brown Adipose Tissue Uncoupling Protein Levels in Mice with Diet-Induced Obesity

Takanobu Shimasaki, Takayuki Masaki*, Kimihiko Mitsutomi, Daisuke Ueno, Koro Gotoh, Seiichi Chiba, Tetsuya Kakuma, Hironobu Yoshimatsu

Department of Internal Medicine 1, Faculty of Medicine, Oita University, Yufu, Japan

Abstract

Objective: Dipeptidyl peptidase (DPP)-4 is responsible for the degradation of several peptides that contain an alanine or proline at the penultimate position or position P1. DPP-4 inhibitors (DPP-4is) have protective effects against type-2 diabetes and several metabolic disorders.

Methods: In the present study, we examined the effects of des-fluoro-sitagliptin (DFS), a DDP-4i, on body adiposity and levels of peroxisome proliferator-activated receptor (PPAR)-α, PPAR-γ coactivator-1 (PGC-1), and uncoupling proteins (UCPs) in mice with diet-induced obesity.

Results: Treatment with DFS dose-dependently decreased the weight of white adipose tissue and serum levels of glucose, compared with controls, without influencing food intake (P<0.05). Additionally, DFS treatment increased the levels of PPAR-α, PGC-1, and UCPs in brown adipose tissue (BAT), and of PPAR-α and UCP3 in skeletal muscle (P<0.05). Furthermore, the effects on BAT PGC-1 and muscle PPAR-α levels were attenuated by treatment with the glucagon-like peptide 1 (GLP-1) antagonist exendin (9–39). Interestingly, hypothalamic levels of proopiomelanocortin (POMC) were increased by DFS treatment and the effects of DFS on PPAR-α, PGC-1, and UCP levels were attenuated in melanocortin (MC)-4 receptor-deficient mice.

Conclusions: In conclusion, high-dose DFS appeared to regulate body adiposity and UCPs in mice with diet-induced obesity, at least partly through a GLP-1 and/or MC-4 pathway.

Introduction

Dipeptidyl peptidase (DPP)-4 is responsible for the degradation of numerous biologically active peptides and chemokines that contain an alanine or proline at the penultimate position or position P1. A DPP-4 inhibitor (DPP-4i) acts by inhibiting the breakdown of regulatory peptides including incretins, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), and increasing insulin release [1]. However, the clinical benefits of DPP-4i therapy are not fully explained by the increased insulin release alone, and other mechanisms are thought to involve effects on β-cell mass, β-cell apoptosis, and other tissues [2].

Recently, extrapancreatic actions of GLP-1 on endothelial cells and the liver have been reported [3,4]. Additionally, effects of DPP-4i and GLP-1 on adipose tissue have been described [5,6]. Studies performed in isolated adipocytes have demonstrated that GLP-1 has the ability to induce both lipogenic and lipolytic mechanisms in white adipose tissue (WAT) [7,8]. These GLP-1 effects in WAT were exerted through a GLP-1-specific receptor, structurally and/or functionally distinct from that expressed in the pancreas [9]. Additionally, chronic DFS treatment decreased body weight gain in mice with diet-induced obesity [10].

In a clinical study, the combined use of DPP-4i and metformin had favorable effects on body weight in type-2 diabetic patients compared with metformin alone [11]. Additionally, almost 61% of patients showed decreased body weight when they used metformin and sitagliptin in the DURATION study [12]. These results suggest that DPP-4i influences adipose tissue and has functional roles in regulating energy metabolism as well as its anti-diabetic effects.

Generally, adipose tissue is classified into brown adipose tissue (BAT) and white adipose tissue (WAT). Uncoupling protein (UCP)-1 in BAT plays a role in energy expenditure and non-shivering thermogenesis [13,14]. UCP2 is expressed ubiquitously in peripheral tissues, including WAT, and UCP3 is expressed primarily in skeletal muscle and adipose tissues [15]. Gene expression of these proteins is regulated by several humoral factors [16–18].
We hypothesized that DFS would affect adiposity and energy metabolism by modulating the expression of UCPs. However, little is known about DFS in modulating energy homeostasis. We investigated the effects of DFS on food intake, body weight, and adiposity, in addition to serum metabolic parameters, such as glucose, free fatty acids (FFAs), triglycerides, and insulin, UCP expression in peripheral tissues, O2 consumption, and the respiratory quotient. The goal of this study was to determine whether DFS has beneficial effects on adiposity, lipid metabolism, and energy expenditure in mice.

**Materials and Methods**

**Animals**

Mature male C57BL/6 mice (C57BL/6; Kbt Oriental, Fukuoka, Japan) and Mc4r-deficient (Mc4r−/−) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA; doi:10.1371/journal.pone.0063626.g001

![Figure 1](image_url)
Wild-type, heterozygotic, and homozygous mice were generated, and pups were genotyped by genomic polymerase chain reaction. C57BL/6 and Mc4rnull/mice were housed in a light-, temperature-, and humidity-controlled room (12/12-h light/dark cycle, lights on/off at 07:00/19:00 h, respectively, 21±1°C, 55±5% relative humidity). All mice were allowed free access to food and drink. The animals were fed a high-fat diet (HFD) that included 60% fat, 20% protein, and 20% carbohydrate, 5.2 kcal/g (Research Diets Inc., New Brunswick, NJ, USA). The high-fat food contained soybean oil (25/773.85 g) and lard (245/773.85). Animals were treated in accordance with the Oita University Guidelines for the Care and Use of Laboratory Animals.

**Materials**

DFS (Merck & Co., Inc. Whitehouse station, NJ, USA) was mixed with HFD in food and used at a dose of 0, 0.12, 0.6, or 1.2 mg/g/day. The dose of DFS was based on both our preliminary findings and a previous report [10].

**Measuring Food intake, Body Weight, and Histological Examination**

To evaluate any dose-response effect of DFS on body weight regulation, DFS mixed with HFD was administered orally at a dose of 0, 0.12, 0.6, or 1.2 mg/g/day for 4 weeks. Body weight, fat weight, serum glucose, and lipid profiles were measured in all animals at the end of the 4-week treatment period. We observed a dose-response effect of DFS and chose to use a dose of 1.2 mg/g/day.

Mice were selected and divided into DFS-treated and non-treated groups. HFD was administered for 8 weeks (from 8 to 16 weeks of age). In the DFS-treated group, DFS was administered orally at a dose of 1.2 mg/g/day for the last 4 weeks. In the control group, HFD with no DFS was given in the same way. Food intake and body weight were measured at 14:30 h daily during the 4 weeks of treatment, and the HFD and DFS were given at 15:00 h. Animals were euthanized 6 h after the last dose. WAT and interscapular BAT were removed and frozen in liquid nitrogen before being stored at −80°C. BAT, skeletal muscle, and epididymal WAT was dissected. The mass of body fat was measured to assess changes in body fat accumulation. The histology of epididymal WAT and levels of the UCPs were measured by immunohistochemistry and stained with hematoxylin and eosin (H&E, ×400). White bars=untreated controls; black bars=DFS-treated mice. Values are the means and standard errors of WAT adipocyte area, circumference, and maximum diameter. **P<0.01 vs. the control group; for adipocytes, n = 5 per group.

doi:10.1371/journal.pone.0063626.g002

Figure 2. Effects of DFS on epididymal WAT, liver, muscle, and BAT in mice with diet-induced obesity. Weight of epididymal WAT (A) and triglyceride (TG) levels in the liver (B) and muscle (C) in HFD mice over the entire 4-week treatment period. White bars = untreated controls; horizontal striped bars = DFS 0.12 mg/g/day; vertical striped bars = DFS 0.6 mg/g/day; black bars = DFS 1.2 mg/g/day. Values are the means and standard errors (n=4 per group). **P<0.01 and *P<0.05 vs. controls. (D) Histological analysis of epididymal WAT, liver, and BAT in DFS-treated and untreated mice. Scale bar=100 μm. Tissues were fixed in formalin and stained with hematoxylin and eosin (H&E, ×400). White bars=untreated controls; black bars=DFS-treated mice. Values are the means and standard errors of WAT adipocyte area, circumference, and maximum diameter. **P<0.01 vs. the control group; for adipocytes, n = 5 per group.
Figure 3. Effects of DFS on oxygen consumption, respiratory quotient, BAT, and muscle in HFD mice. (A & B) Effects of DFS on respiratory quotient (RQ) and oxygen consumption. Light phase after vehicle treatment (CL) and dark phase after vehicle treatment (CD); light phase after DFS treatment (DL) and dark phase after DFS treatment (DD). Effects of DFS on relative levels of PPAR-α, PGC-1α, and UCPs in BAT (C), and of PPAR-α and UCP3 protein expression in muscle (D). Representative Western blots of PPAR-α, PGC-1α, and UCPs protein levels are shown. White bars = untreated controls; black bars = DFS-treated mice. Values are the means and standard errors (n = 3–5 per group). *P < 0.05, **P < 0.01 vs. controls. r.a.u., relative arbitrary unit.

doi:10.1371/journal.pone.0063626.g003
assessed in all animals at the end of the last 4 weeks of the treatment period.

To evaluate the effects of the GLP-1 receptor antagonist exendin (9–39), DFS-treated mice were injected intraperitoneally once daily for 5 d with either exendin (9–39) (25 nmol/L/kg) or saline. Each group was pair-fed.

Mc4r<sup>−/−</sup> and C57BL/6 mice were divided into DFS-treated and non-treated groups to investigate the effects of DFS on the POMC pathway. Each group was fed HFD with or without DFS at a dose of 1.2 mg/g/day and was pair-fed for 2 weeks.

**Blood Samples**

We measured body weight at 14:30 h and took blood for hormone tests at 15:00 h. Blood was collected after a 16-h fast; serum was separated and frozen immediately at −20°C until assayed. Serum levels of glucose, insulin, triglycerides, and FFAs were measured using commercial kits (Wako Chemical, Tokyo, Japan). Serum concentrations of active GLP-1 (IBL, Tokyo, Japan), leptin (Morinaga, Tokyo, Japan), TNF-α, and IL-1β (Invitrogen, Tokyo, Japan) were measured by sandwich enzyme immunoassay using commercially available kits.

**Triglycerides in Liver and Muscle**

Liver and muscle (100 mg) were homogenized in 2 mL of a solution containing 150 mM NaCl, 0.1% Triton X-100, and 10 mM Tris (pH 7.4), using a Polytron homogenizer (NS-310E; MicroTech Nichion, Chiba, Japan) for 1 min. The triglyceride content of 100 μL of this solution was determined using a commercial kit (Wako Pure Chemical, Osaka, Japan).

**Histological Analyses**

Small pieces of epididymal WAT, BAT, and muscle were dissected, washed in saline, fixed in 10% formalin, and embedded in paraffin. Tissue sections were cut at a thickness of 20 μm and stained with hematoxylin and eosin. All images were captured with a Biorevo BZ-9000 microscope (Keyence, Osaka, Japan), and morphometric analyses of WAT were performed using measurement-module software (Biorevo BZ-H2A; Keyence).

**Western Blotting**

Western blotting was performed as described previously [19]. Frozen tissues were homogenized in Tris buffer (pH 7.4), centrifuged, and boiled. The total protein concentration of the tissue was quantified using the Bradford method [20]. After determining the total protein concentration, an equal amount of total protein was loaded on 8% sodium dodecyl sulfate-polyacrylamide gels for electrophoresis and was then transferred electrophoretically onto a polyvinylidene difluoride membrane (Bio-Rad Laboratories, Richmond, CA, USA). Membranes were blocked with 0.4% bovine serum albumin for 5 min and then incubated for 1 h with primary antibodies at room temperature and then for 1 h at room temperature with the secondary antibody. The primary antibody solution consisted of a polyclonal antiserum (5 g/L) with specificity for UCP1 (catalog no. sc-6529), UCP2 (catalog no. sc-6526), UCP3 (catalog no. sc-7756), PPAR-α (catalog no. sc-9000), PGC-1α (catalog no. sc-13067), POMC (catalog no. sc-20148), and α-tubulin (catalog no. sc-5546) (Santa Cruz Biotechnology). Several markers were detected by enhanced chemiluminescence (Amersham Life Science, Buckinghamshire, UK) and quantitated using a ChemiDoc XRS system (Bio-Rad, Hercules, CA, USA).

Figure 4. Effects of exendin (9–39) on weight and serum active GLP-1 levels in DFS-treated mice. (A) Body weights of saline-treated mice and mice treated with the GLP-1 receptor antagonist exendin (9–39) (Ex). Black squares and solid lines = saline-treated group; black triangles and dashed lines = Ex-treated group. (B) Comparison of changes in body weight at the end of the study. (C) Average daily food intake over the entire 5-day treatment period. Ex-treated and saline-treated mice were pair-fed. Black bars = saline-treated group; striped bars = Ex-treated group. (D) Serum levels of active GLP-1 in DFS-untreated controls, DFS-treated saline-treated (DFS) mice, and DFS-treated exendin (9–39)-treated (DFS + Ex) mice. White bars = control; black bars = DFS; striped bars = DFS + Ex. Values are the means and standard errors (n = 3–4 per group). *P < 0.05 vs. the DFS group, ††P < 0.01 vs. the control group.

doi:10.1371 journal.pone.0063626.g004
Changes in the Levels of TNF-α and IL-1β after DFS Treatment

The level of circulating IL-1β, but not TNF-α, was lower in the DFS group than in the control group (22.0 ± 0.2 pg/mL vs. 28.5 ± 1.1 pg/mL, P < 0.05). In contrast, the circulating level of IL-1β was not significantly different in the DFS-treated Mch−/− animals (51.3 ± 0.5 pg/mL in DFS-treated animals vs. 60.5 ± 11.7 pg/mL in controls, P > 0.1).

Effects of DFS Treatment on Triglyceride Content of Liver and Muscle, and Morphology of Liver and BAT

DFS treatment decreased the triglyceride contents of liver and muscle tissue, compared with controls (P < 0.01 for liver triglycerides; Fig. 2B; P < 0.05 for muscle triglycerides; Fig. 2C). Figure 2D shows the morphology of the epididymal WAT, liver, and BAT; cell size in epididymal WAT decreased in the DFS group compared with the controls (P < 0.01 for adipocyte area, circumference, and diameter; Fig. 2D).

Effects of DFS Treatment on Oxygen Consumption and RQ

Oxygen consumption and RQ were assessed pretreatment and 24 h after DFS treatment. Treatment with DFS did not increase oxygen consumption (Fig. 3A) but did decrease the RQ (P < 0.05; Fig. 3B), compared with the controls.

Effects of DFS on BAT PPAR-α, PGC-1α, UCPs, Muscle PPAR-α, and UCP3 Levels

Figure 3C shows the change in BAT PPAR-α, PGC-1α, and UCPs levels after treatment with DFS. BAT PPAR-α, PGC-1α, UCP1, UCP2, and UCP3 levels increased, by 117%, 123%, 679%, 119%, and 147%, respectively, after treatment with DFS, compared with the controls (P < 0.05; Fig. 3C). No significant change occurred in WAT UCP2 levels in the DFS group, compared with controls (data not shown). Figure 3D shows that muscle PPAR-α and UCP3 levels were increased, by 109% and 110%, respectively, after treatment with DFS, compared with untreated mice (P < 0.05, Fig. 3D).

Effects of GLP-1 Antagonist Treatment on Body Weight and Serum Active GLP-1 Levels in DFS-treated Mice with Diet-induced Obesity

The effect of DFS on body weight was partially attenuated by the GLP-1 antagonist exendin (9–39) compared with salin-treated mice (−2.1 ± 0.4 g/5 days in exendin (9–39)-treated mice vs. −3.1 ± 0.2 g/5 days in salin-treated mice, P < 0.05 for body weight change; Fig. 4, A and B). There was no significant difference in daily food intake (Fig. 4C) or serum active GLP-1 levels (16.8 ± 1.6 pg/mL in exendin (9–39)-treated mice vs. 17.1 ± 2.6 pg/mL in salin-treated mice, P > 0.1; Fig. 4D) between exendin (9–39)- and salin-treated mice. However, treatment with DFS elevated the serum active GLP-1 level almost 2.5-fold compared with controls (17.1 ± 2.6 pg/mL in DFS-treated mice vs. 7.4 ± 1.7 pg/mL in controls, P < 0.01; Fig. 4D).

Indirect Calorimetry

In vivo indirect calorimetry was performed using the Oxymax system (Columbus Instruments, Columbus, OH, USA). Constant airflow (0.6 l/min) was drawn through the chamber and monitored using a flow meter. To calculate oxygen consumption (VO₂), carbon dioxide production and respiratory quotient (RQ; ratio of carbon dioxide production to VO₂) were monitored at the inlet and outlet of the scaled chambers. The animals were randomly placed into the experimental chambers with free access to food and water. Mice were housed individually in cages, through which air of known O₂ concentration was passed at a constant flow rate. Calorimetry was performed after treatment with DPP-4i during light and dark phases. VO₂ and RQ samples were collected approximately every 15 min for 24 h. For each time point, the samples for each group during the light and dark phases were averaged. The samples for each group were averaged for each time point.

Statistical Analyses

All data are expressed as means ± SEM. We used ANOVA with a post hoc Fisher’s protected least significant difference test to analyze differences with multiple comparisons (StatView 5.0; SAS Institute, Cary, NC, USA), or the Mann-Whitney U-test, where appropriate. In the dose-dependency study, we used a simple regression test and Pearson’s coefficient test.

Results

Effects of DFS Treatment on Food Intake, Body Weight, WAT Weight, Serum Glucose, Insulin, FFAs, Triglycerides and Leptin in Mice with Diet-induced Obesity

Figure 1A shows the dose-dependent effect of DFS on body weight (DFS dose: 0, 0.12, 0.6, or 1.2 mg/g/day; P < 0.001, r² = 0.927; Fig. 1A). Figure 1B shows the time course of body weight in mice treated with DFS for 4 weeks (DFS dose: 0.12 mg/g/day) and untreated mice (P < 0.05; Fig. 1B). There was no significant difference in daily food consumption between DFS-treated (DFS dose: 0.12, 0.6, or 1.2 mg/g/day) and untreated mice with diet-induced obesity, nor in body weight change between DFS-treated (DFS dose: 0.12 mg/g/day) and untreated mice (P > 0.1; Fig. 1A, C and D). Between DFS-treated (DFS dose: 0.6 or 1.2 mg/g/day) and untreated, significant differences did exist (P < 0.05 for each; Fig. 1B and C). Additionally, serum glucose and insulin levels decreased in the DFS group (DFS dose: 1.2 mg/g/day), compared with the controls (P < 0.01 for serum glucose; Fig. 1E) (P < 0.05 for serum insulin; Fig. 1F). There were no significant differences in serum triglyceride or FFA levels between the DFS group and controls (P > 0.05 for serum triglycerides; Fig. 1G) (P > 0.1 for serum FFAs; Fig. 1H). Epididymal adiposity was attenuated in the DFS group (DFS dose: 1.2 mg/g/day) compared with controls (P < 0.01 for epididymal WAT; Fig. 2A). Serum leptin levels were lower in the DFS group than in the control group (7.9 ± 1.6 ng/mL vs. 13.3 ± 2.5 ng/mL, P < 0.05).
Effects of DFS on BAT PGC-1α, UCP1, UCP2, Muscle PPAR-α, and UCP3 Levels in Animals Treated with a GLP-1 Antagonist

Figure 5A shows the morphology of the BAT, liver, and epididymal WAT; cell size in epididymal WAT increased in the DFS group treated with the GLP-1 antagonist exendin (9–39) compared to the saline-treated DFS group (P < 0.01 for adipocyte area, circumference, and diameter; Fig. 5A). The effects of DFS on BAT PGC-1α, UCP2, and muscle PPAR-α levels were partly attenuated by the GLP-1 antagonist (P < 0.05 for BAT PGC-1α, BAT UCP2, and muscle PPAR-α; Fig. 5B and C). In contrast, the muscle UCP3 level was increased by 176% by the GLP-1 antagonist compared with the saline-treated DFS group (P < 0.05 for muscle UCP3; Fig. 5C). There was no significant change in the effect of DFS on the BAT UCP1 level in mice treated with the GLP-1 antagonist (P > 0.1 for BAT UCP1; Fig. 5B).

Figure 5A

Effects of DFS Treatment on Hypothalamic POMC Protein Levels in B57BL/6 Mice, and on Body Weight and WAT Weight in Mc4r<sup>2/2</sup> Mice

DFS treatment increased the hypothalamic POMC protein level compared to controls (14.6 ± 1.5 r.a.u. in DFS-treated mice vs. 9.2 ± 0.9 r.a.u. in controls, P < 0.05; Fig. 6A). Body weight and epididymal adiposity were attenuated in the DFS-treated C57BL/6 mice compared to untreated mice (P < 0.05 for body weight change; Fig. 6B). There were no significant differences in body weight and epididymal adiposity between DFS-treated and non-treated Mc4r<sup>2/2</sup> mice (P > 0.1 for body weight change; Fig. 6B) (epididymal WAT: data not shown). Each group was pair-fed for 2 weeks (Fig. 6C).

The effects of DFS on body weight and WAT weight were not observed in Mc4r<sup>2/2</sup> mice.

Figure 6A

Effects of DFS on BAT PPAR-α, PGC-1α, UCPs, Muscle PPAR-α, and UCP3 Levels in Mc4r<sup>2/2</sup> Mice

Figure 7A shows the morphologies of the BAT, liver, and epididymal WAT; there was no significant change in cell size in epididymal WAT in the DFS group, compared to the control group (P > 0.1 for adipocyte area, circumference, and diameter; Fig. 7A). The effects of DFS on BAT PPAR-α, PGC-1α, UCPs, muscle PPAR-α, and UCP3 levels were partially attenuated in Mc4r<sup>2/2</sup> mice (P > 0.1 for BAT UCP1 and muscle UCP3; Fig. 7, B and C).

Discussion

This study demonstrated that DFS attenuated body adiposity, without affecting food intake, in C57BL/6 mice with diet-induced obesity. Additionally, DFS treatment dose-dependently decreased body weight gain.

We examined how DFS reduced body adiposity; our results demonstrated that the administration of DFS did not affect food intake. Given this, the effect of DFS on energy metabolism may be an important factor in the DFS-induced reduction in adiposity. UCP is an inner mitochondrial membrane transporter of FFAs that dissipates the proton gradient by releasing stored energy, as heat [21]. UCP1 in BAT plays a crucial role in regulating energy expenditure and thermogenesis in rodents and the mammalian neonates, including humans [22]. Our study demonstrated that DFS treatment increased BAT UCP1 levels, reflecting a DFS-induced increase in energy expenditure. In addition to the change in BAT UCP1, in this study, DFS treatment increased muscle UCP3 protein expression. The functional meaning of this is...
currently unclear. It has been suggested that UCP3 contributes to the export of fatty acids from the mitochondrial matrix, rather than the regulation of energy expenditure [23]. The export of fatty acids from the mitochondrial matrix by UCP3 may prevent the accumulation of fatty acids in mitochondria and help to maintain muscular fat oxidative capacity. The DFS-induced up-regulation of muscle UCP3 might also contribute to regulating fatty acid mobilization and utilization. In this study, we confirmed the functional role of the DFS-induced increase in UCP1 protein level in BAT using calorimetry. In fact, DFS treatment did not change O$_2$ consumption but decreased the respiratory quotient. This suggests that high-dose DFS treatment decreases the use of carbohydrates and increases the use of fat, which may also contribute to the reduction in body fat.

DPP-4Is stabilize postprandial levels of bioactive GLP-1 and GIP [2] and have been approved for the treatment of type 2 diabetes. DPP-4Is exert their actions predominantly through potentiation of GLP-1 signaling [10]. A possible involvement of DFS in regulating adiposity has been suggested: perhaps a direct action of DFS on GLP-1 levels [24,25]. Indeed, in the present study, the effects of DFS on body weight, and UCPs were partially attenuated with a GLP-1 antagonist. It is also possible that other factors mediate the accelerating effect of DFS on UCP1. We cannot exclude the possible involvement of the central nervous system because BAT UCP1 is regulated by the hypothalamus and brainstem, through activation of the sympathetic nervous system [26–28]. In fact, POMC levels were increased by DFS treatment. Furthermore, the effects of DFS on body weight, WAT weight, and UCPs were attenuated in Mc4r$^{-/-}$ mice. HFD-induced obesity in mice increases hyperleptinemia and hypothalamic leptin resistance through induction of suppressor of cytokine signaling (SOCS)-3 [29]. Increased SOCS-3 expression in POMC neurons inhibits activation of signal transducer and activator of transcription (STAT)-3 and results in hyperphasia and obesity [30]. Several researchers have clinically investigated the anti-inflammatory and SOCS-3 suppressive effects of sitagliptin and exenatide, a GLP-1 receptor agonist [31,32]. In the present study, treatment with DFS elevated serum levels of active GLP-1 compared with controls. In addition, GLP-1 antagonist treatment attenuated the DFS-induced body weight decrease. This suggests that the effects of DFS on GLP-1 and SOCS-3 are involved in the DFS-induced body weight decrease.

Figure 7. Effects of DFS on BAT, liver, WAT, and muscle in Mc4r$^{-/-}$ mice. (A) Histological analysis of BAT, liver, and epididymal WAT in DPP-4i des-fluoro-sitagliptin (DFS)-treated and non-treated Mc4r$^{-/-}$ mice. Scale bar = 100 μm. Tissues were fixed in formalin and stained with hematoxylin and eosin (H&E, ×400). Values are the means and standard errors of WAT adipocyte area and circumference and maximum diameter of adipocytes (n = 5 per group). Effects of DFS on BAT (B) and muscle (C) in Mc4r$^{-/-}$ mice. Representative Western blots of PPAR-α, PGC-1α, and UCP protein levels are shown. White bars = untreated mice (control group); black bars = DFS-treated mice (DFS group). Values are the means and standard errors (n = 3 per group). r.a.u., relative arbitrary unit.

doi:10.1371/journal.pone.0063626.g007
DFS are partly dependent on an increase in the GLP-1 concentration. This study demonstrated that DFS attenuated body adiposity, without affecting food intake, suggesting DFS effectively accelerated energy expenditure through a GLP-1 and/or MC-4 pathway. Taken together, DFS appears to regulate body adiposity and UCPs in mice with diet-induced obesity, at least partly through a GLP-1 and/or MC-4 pathway.

Somewhat surprising was the observation that mice treated with DFS also exhibited attenuation of weight gain on a high-fat diet. This is in contrast to a clinical study of sitagliptin. There, sitagliptin monotherapy demonstrated significant reductions in HbA1c; however, it had a neutral effect on body weight relative to baseline [33]. Continuous administration of DFS in the food in our study probably achieves more potent and sustained 24-h inhibition of DPP-4 activity relative to the twice-daily administration of vildagliptin used in previous experiments [34]. These findings may be explained in part by species-specific differences in energy homeostasis, arising as a result of loss of DPP-4 activity. Clinically, the combined use of DPP-4i and metformin has favorable effects on body weight in type-2 diabetic patients compared with that of a sulfonylurea and metformin [35]. Additionally, the combined use of pioglitazone and sitagliptin did not significantly worsen pioglitazone-induced body weight gain [36]. Furthermore, almost 61% patients showed decreased body weight when they used metformin and sitagliptin in the DURATION study [12]. The results indicated that DPP-4i may regulate body adiposity under the specific conditions that accelerated the effects of DPP-4i or combined other nutritional/environmental factors. Indeed, the effects of DPP-4i are not observed with a normal diet (unpublished data).

The present study has several limitations. First, the dose is relatively high compared with human doses. It may thus be worthwhile to investigate similarities and dissimilarities between humans and rodents. Second, the involvement of weight loss in other major organs, such as the liver, remains unresolved. Third, we did not determine the peripheral effects of DFS on energy homeostasis, including mitochondrial counts, in BAT. Further studies are necessary to address in more detail the mechanism(s) by which DFS affects energy metabolism.

In conclusion, DFS appears to regulate body adiposity and energy expenditure in mice with diet-induced obesity, partly through GLP-1 and/or MC-4 pathways.

The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/NeMnt9.

Author Contributions
Conceived and designed the experiments: TS TM. Performed the experiments: TS TM KM DU SC. Analyzed the data: TS TM KG. Contributed reagents/materials/analysis tools: TS TM TK. Wrote the paper: TS HY.

References
1. Mendlein R (1999) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85: 9–24.
2. Thornberry NA, Gallwitz B (2009) Mechanism of action of inhibitors of dipeptidyl-peptidase-IV (DPP-4). Best Pract Res Clin Endocrinol Metab 23: 479–496.
3. Lehre K, Marx N (2011) Cardiovascular effects of incretin-based therapies. Rev Diabet Stud 8: 382–391.
4. Abu-Hamadah R, Rabiee A, Menelli GS, Shannon RP, Andersen DK, et al. (2009) Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 94: 1841–1852.
5. Shirakawa J, Fuji H, Ohnuma K, Sato K, Ito Y, et al. (2011) Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60: 1246–1257.
6. Ding X, Sauras NR, Lin S, Gupta NA, Anania FA (2006) Exendin-4, a glucagon-like-peptide-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43: 173–181.
7. Villaneuva-Penacarrillo ML, Marquez L, Gonzalez N, Diaz-Miguel M, Valverde I (2000) Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res 32: 73–77.
8. Vendrell J, El Bekay R, Peral B, Garcia-Fuentes E, Megia A, et al. (2011) Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology 152: 4072–4079.
9. Polakos S, Miguez JM, Soropias JL (2011) Evidence for a gut-brain axis by glucagon-like-peptide-1 to elicit hyperglycaemia in fish. J Neuroendocrinol 23: 500–510.
10. Lamont BJ, Drucker DJ (2000) Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat-Fed Mice. Diabetes 57: 190–196.
11. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, et al. (2008) Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Current Medical Research and Opinion 24: 537–550.
12. Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, et al. (2010) Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 94: 1841–1852.
13. Himms-Hagen J, Harper M-F (2001) Physiological Role of UCP3 May Be Indispensable for the Adaptive Non-Shivering Thermogenesis. Endocrinology 151: 4109–4115.
14. Mostyn A, Bos PM, Litten JC, Laws J, Symonds ME, et al. (2008) Differential effects of thyroid hormone manipulation and beta adrenoceptor agonist administration on uncoupling protein mRNA abundance in adipose tissue and thermoregulation in neonatal pigs. Organogenesis 4: 182–187.
15. Arakawa M, Masaki T, Nishimura J, Seike M, Yoshimatsu H (2011) The effects of branched-chain amino acid granules on the accumulation of tissue triglycerides and uncoupling proteins in diet-induced obese mice. Endocrinology 150: 161–170.
16. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.
17. Masaki T, Yoshimichi G, Chiba S, Yasuda T, Noguchi H, et al. (2003) Coroctinopulin-releasing hormone-mediated pathway of leptin to regulate feeding, adiposity, and uncoupling protein expression in mice. Endocrinology 144: 3547–3554.
18. Montyn A, Bos PM, Litten JC, Laws J, Symonds ME, et al. (2008) Differential effects of thyroid hormone manipulation and beta adrenoceptor agonist administration on uncoupling protein mRNA abundance in adipose tissue and thermoregulation in neonatal pigs. Organogenesis 4: 182–187.
19. Cannon B, Nederhaard J (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84: 277–359.
20. Hamms-Hagen J, Harper M-F (2001) Physiological Role of UCP3 May Be Export of Fatty Acids from Mitochondria When Fatty Acid Oxidation Predominates: An Hypothesis. Experimental Biology and Medicine 226: 78–94.
21. Mu J, Woods J, Zhou Y-P, Roy RS, Li Z, et al. (2006) Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes. Diabetes 55: 1705–1704.
22. Sangle GV, Lauffer LM, Greico A, Trivedi S, Iakoubov R, et al. (2012) Novel Biological Action of the Dipeptidylpeptidase-IV Inhibitor, Sitagliptin, as a Glucagon-Like Peptide-1 Secretagogue. Endocrinology 153: 564–573.
23. Richard D, Picard F (2011) Brown fat biology and thermogenesis. Front Biosci 16: 1293–1260.
24. Zaninovich AA (2001) [Thyroid hormones, obesity and brown adipose tissue thermogenesis]. Medicina (B Aires) 61: 597–602.
25. Yasuda T, Masaki T, Sakata T, Yoshimatsu H (2004) Hypothalamic neuronal histamine regulates sympathetic nerve activity and expression of uncoupling protein 1 mRNA in brown adipose tissue in rats. Neuroscience 125: 535–540.
26. Morrisson CD, Haypens P, Stewart LK, Gettsy TW (2009) Implications of crosstalk between leptin and insulin signaling during the development of diet-induced obesity. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1792: 489–496.
27. Thaler JP, Schwartz MW (2010) Minireview: Inflammation and Obesity Pathogenesis: The Hypothalamus Heats Up. Endocrinology 151: 4109–4115.
31. Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, et al. (2012) Sitagliptin Exerts an Antinflammatory Action. Journal of Clinical Endocrinology & Metabolism 97: 3333–3341.
32. Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, et al. (2012) Exenatide Exerts a Potent Antinflammatory Effect. Journal of Clinical Endocrinology & Metabolism 97: 198–207.
33. Derosa G, Maffioli P, Salvadeo SAT, Ferrari I, Ragonesi PD, et al. (2010) Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 59: 887–895.
34. Raum K, von Voss P, Gottfredsd CF, Grobuzinska V, Rolim B, et al. (2007) Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not. Diabetes 56: 8–15.
35. Nauck MA, Meining G, Sheng D, Terranella I, Stein PP, et al. (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism 9: 194–205.
36. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28: 1556–1568.